Search clinical trials for: Optimized Background Regimen (OBR)

Total 106 results

Otsuka Pharmaceutical Development & Commercialization...

Terminated

Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis

Tuberculosis

Latvia, Lithuania
National Institute of Allergy and Infectious Diseases...
Otsuka Pharmaceutical Development & Commercialization, Inc.

Recruiting

Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB

HIV Infections | Tuberculosis

Tanzania, India, South Africa, Botswana
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

Tuberculosis, Pulmonary | Extensively Drug-Resistant Tuberculosis | Tuberculosis, Multidrug Resistant

Korea, Republic of, China, United States, Egypt, Estonia, Japan, Latvia, Peru, Philippines
Otsuka Pharmaceutical Development & Commercialization...

Completed

A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)

Multidrug Resistant Tuberculosis

Philippines, South Africa
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis

Tuberculosis | Rifampicin Resistant Tuberculosis

Brazil, India, South Africa, Tanzania, Thailand
Gilead Sciences

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

HIV-1-infection

United States, Spain, France, Taiwan, Japan, Thailand, Dominican Republic, Germany, Canada, Italy, South Africa
TaiMed Biologics Inc.

Completed

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

HIV

United States, Taiwan, Puerto Rico
Myrexis Inc.

Terminated

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

HIV Infections

Canada, United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

HIV-1

United States, France, Spain, Portugal, Canada, United Kingdom, South Africa, Argentina, Brazil, Puerto Rico, Thailand, Netherlands, Romania
ViiV Healthcare
Pfizer

Completed

Prospective Observational Epidemiologic Study of Maraviroc's Safety (POEM)

Human Immunodeficiency Virus

United States, Canada, Spain, Belgium, France, United Kingdom, Italy, Brazil, Puerto Rico, Germany, Greece
Otsuka Pharmaceutical Development & Commercialization...

Completed

Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis

Pediatric | Multidrug Resistant Tuberculosis

Philippines, South Africa
United BioPharma

Not yet recruiting

UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients

HIV-1 Infection
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Completed

Renal Denervation in Hypertension (DENER-HTN)

Hypertension, Resistant to Conventional Therapy | Renal Denervation

France
TaiMed Biologics Inc.
Westat

Completed

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

HIV

United States, Puerto Rico
CytoDyn, Inc.

Completed

Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140 (PRO140)

HIV

United States, Puerto Rico
Hoffmann-La Roche

Completed

Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection

HIV Infections

France
Boston University
National Institute of Allergy and Infectious Diseases (NIAID); Centers for... and other collaborators

Completed

Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB (Opti-Q)

Tuberculosis, Multidrug-Resistant

South Africa, Peru
Janssen Research & Development, LLC

Recruiting

Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB

Multidrug-Resistant Tuberculosis

Mozambique, Philippines, Russian Federation, South Africa, Uganda, Ukraine
Janssen Infectious Diseases BVBA

Completed

To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.

Tuberculosis

China, Ukraine, Korea, Republic of, Peru, Estonia, Kenya, Latvia, Philippines, Russian Federation, South Africa, Thailand, Turkey
ViiV Healthcare
GlaxoSmithKline

Completed

PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)

Infection, Human Immunodeficiency Virus I
Bamrasnaradura Infectious Diseases Institute
Department of Disease Control, Thailand

Completed

Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure (BIDI-MONO)

HIV | AIDS | Treatment Failure | Lopinavir

Thailand
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
Merck Sharp & Dohme LLC

Completed

Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672) (VICTOR-E1)

HIV Infections
Janssen Infectious Diseases BVBA

Completed

TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).

Tuberculosis

South Africa, Peru, Latvia, Philippines, Russian Federation, Thailand, Brazil, India
Janssen Pharmaceutical K.K.

Completed

An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)

Tuberculosis, Multidrug-Resistant

Japan
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

HIV Infections

Canada, United States, United Kingdom, Netherlands, Australia, Germany, Spain, Belgium, Switzerland
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Unknown

Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer (BREC-AGC)

Advanced Gastric Cancer
Hoffmann-La Roche
Trimeris

Completed

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

HIV Infections

United States, Canada, Puerto Rico
Hoffmann-La Roche

Completed

INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.

HIV Infections

France
Juan A. Arnaiz

Unknown

Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (RALAM)

AIDS

Spain
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects (MOTIVATE 2)

HIV Infections

Netherlands, United States, Italy, Spain, United Kingdom, France, Germany, Australia, Switzerland, Belgium, Canada, Poland, Sweden
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects (MOTIVATE 1)

HIV Infections

United States, Canada
Gilead Sciences

Terminated

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

HIV Infections | Acquired Immune Deficiency Syndrome (AIDS)

United States, Thailand, Spain, Uganda, South Africa, Italy
Shandong Provincial Hospital

Unknown

Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma

Lymphoma, Non-Hodgkin;Hodgkin Disease

China
French National Agency for Research on AIDS and...
Merck Sharp & Dohme LLC; Janssen-Cilag Tibotec

Completed

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses (ANRS139 TRIO)

HIV Infections

France
Janssen Research & Development, LLC

Completed

A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

HIV

Italy, Thailand, Spain, Uganda, Portugal, South Africa
be Medical

Terminated

Endovascular Treatment of Peripheral Artery Disease (PAD)

Peripheral Arterial Disease | Iliac Artery Disease | Femoropopliteal Occlusive Disease | Below-the-knee Obstruction

Belgium
Hoffmann-La Roche
Trimeris

Terminated

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients (AMICI)

HIV Infections

United States, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Completed

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

HIV Infections

United States, Germany, Spain, France, Australia, Canada, Belgium, Netherlands, United Kingdom, Japan
Boehringer Ingelheim

Terminated

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

HIV Infections

United States, Argentina, Brazil, Canada, Germany, Italy, Spain
Federation Francophone de Cancerologie Digestive
Roche Pharma AG

Completed

1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer

Colorectal Cancer

France
Fudan University
Henan Cancer Hospital

Completed

Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Chemotherapy Effect

China
Affiliated Cancer Hospital & Institute of Guangzhou...
Zhejiang Cancer Hospital; Guangdong Provincial Hospital of Traditional Chinese... and other collaborators

Unknown

Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2 (EHTLAGCRGD2)

Gastric Cancer

China
Gilead Sciences

Completed

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

HIV Infection

Canada, Germany, United States, Spain, France, Australia, Puerto Rico, Italy, Belgium, Mexico, Switzerland, Portugal, Netherlands, United Kingdom
NYU Langone Health

Completed

The Use of Serratus Block for Cardiac Surgery

Cardiac Surgery

United States
Instituto do Coracao
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Evaluation in the Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction With Conventional Blood Culture.

Sepsis | Fungemia | Bacteremia

Brazil
Sanofi
Hanmi Pharmaceutical Company Limited

Terminated

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea (AMPLITUDE-S)

Type 2 Diabetes Mellitus

United States, China, Taiwan
HeNan Sincere Biotech Co., Ltd
Beijing YouAn Hospital; Beijing Ditan Hospital; Peking Union Medical College... and other collaborators

Completed

A Drug Safety and Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV Treatment (FNC)

AIDS

China
Janssen-Cilag S.p.A.

Completed

Non-interventional Study on Use of Darunavir With Ritonavir in Clinical Practice

HIV Infections
University Hospital, Strasbourg, France

Active, not recruiting

Personalized Non-invasive Neuromodulation by rTMS for Chronic and Treatment Resistant Catatonia (RETONIC)

Schizophreniform Catatonia | Treatment Resistant

France

3

Subscribe